Bifidobacterium longum – W11 (LMG P-21586)

DAILY DOSAGE IN CLINICAL STUDY
1,2,3,4,5,6,7) 5 billion CFU + FOS

FUNCTIONALITY
Reduction of gastro-intestinal discomfort related to IBS • Rebalance of intestinal microbiota • Non-transmissible rifamycins resistance • Production of Exopolysaccharides

Human clinical trials
1) Amenta M. et al. Diet and chronic constipation. Benefits of oral supplementation with symbiotic zir fos (Bifidobacterium longum W11 + FOS Actilight). Acta Biomed 2006; 77(3):157-62.
2) Colecchia A. et al. Effect of a symbiotic preparation on the clinical manifestations of irritable bowel syndrome, constipation-variant. Results of an open, uncontrolled multicenter study. Minerva Gastroenterol Dietol 2006; 52(4):349-58.
3) Fanigliulo L. et al. Role of gut microflora and probiotic effects in the irritable bowel syndrome. Acta Biomed 2006; 77(2):85-9.
4) Sarnelli G. et al. Effects of oral supplementation with the symbiotic (Bifidobacterium longum W11 + FOS Actilight) on IBS with constipation: a randomized, dose finding trial, versus fibers. Digestive and Liver Disease 2008; 40(1):S141.
5) Malaguarnera M. et al. Bifidobacterium longum with fructo-oligosaccharides (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci 2007; 52:3259-3265.
6) Dughera L. et al. Effects of symbiotic preparation on constipated irritable bowel syndrome symptoms. Acta Biomed 2007; 78:111-116.
7) Del Piano M. et al. Clinical Experience With Probiotics in the Elderly on Total Enteral Nutrition. J Clin Gastroenterol 2004;38:S111-S114.

In vitro studies
a) Graziano T. et al. The possible innovative use of Bifidobacterium longum W11 in association with rifaximin: a new horizon for combined approach? J Clin Gastroenterol. 2016 Nov/Dec;50 Suppl 2, Proceedings from the 8th Probiotics, Prebiotics & New Foods for Microbiota and Human Health meeting held in Rome, Italy on September 13-15, 2015:S153-S156.
b) Inturri R. et al. Complete Genome Sequence of Bifidobacterium longum W11 (LMG P-21586), Used as a Probiotic Strain. Genome Announc. 2017 Mar 9;5(10). pii: e01659-16. doi: 10.1128/genome A.01659-16.
c) Inturri R. et al. Chemical and biological properties of the novel exopolysaccharide produced by a probiotic strain of Bifidobacterium longum, Carbohydrate polymers / Elsevier 2017.
d) Medina et al. Differential immunomodulatory properties of Bifidobacterium longum strains: relevance to probiotic selection and clinical applications, Clinical and Experimental Immunology, 2007.
e) Izquierdo E. et al. Resistance to Simulated Gastrointestinal Conditions and Adhesion to Mucus as Probiotic Criteria for B. longum strains. Curr Microbiol 2008, 56:613-618.
f) Interri R. et al. Scanning Electro Microscopy Observation of Adhesion Properties of B. longum W11 and Chromatographic Analysis of Its Exopolysaccharide 2014, Food and Nutrition Sciences 1787-1792.
g) Interri R. et al. Immunomodulatory Effects of B. longum W11 Produced Exopolysaccharide on Cytokine Production. 2017, Current Pharmaceutical Biotechnology.
h) B. longum W11, an antibiotic resistant probiotic, Di Pierro 2018, CEC online article: http://ceceditore.com/bifidobacterium-longum-w11-anantibiotic-resistant-probiotic/?lang=en.

DAILY DOSAGE IN CLINICAL STUDY
5 billion CFU + FOS

FUNCTIONALITY
Hepatic encephalopathy

Human clinical trial
Malaguarnera M. et al. Bifidobacterium longum with fructo-oligosaccharides (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci 2007; 52:3259-3265.